慢性乙型肝炎临床治愈预测指标  

Predictors of clinical cure for chronic hepatitis B

作　　者：刘晨瑞 李亚萍[1] 党寒香 何玲[1] 党双锁[1] Liu Chenrui;Li Yaping;Dang Hanxiang;He Ling;Dang Shuangsuo(Department of Infection,The Second Affiliated Hospital of Xi’an Jiaotong University,Xi’an 710004,Shaanxi,China)

机构地区：[1]西安交通大学第二附属医院感染科,陕西西安710004

出　　处：《中国肝脏病杂志(电子版)》2024年第4期1-7,共7页Chinese Journal of Liver Diseases:Electronic Version

基　　金：国家重点研发计划“病原学与防疫技术体系研究”(2023YFC2308102);西安交通大学第二附属医院院基金自由探索项目-2020(2020YJ(ZYTS)175)。

摘　　要：慢性乙型肝炎(chronic hepatitis B,CHB)临床治愈的研究进展迅速,以聚乙二醇干扰素(peginterferon,Peg-IFN)为基础的治疗方案是CHB临床治愈的主要方案。治疗基线和治疗中病毒载量水平及乙型肝炎病毒血清学标志物等指标变化是预测疗效的重要指标。随着治疗的精细化管理,对CHB临床治愈预测因素的探索取得了一定进展。本文从宿主及病毒两方面对CHB临床治愈疗效的预测指标进行总结,以期为临床实践提供参考。Research on the clinical cure of chronic hepatitis B(CHB)is progressing rapidly,and the treatment regimen based on pegylated interferon(Peg-IFN)is the main regimen for the clinical cure of CHB.Changes from baseline,on-treatment viral quantitative levels and hepatitis B virus serologic markers are important predictors of efficacy.With the requirement of refined management of treatment,some progress has been made in exploring the predictors of clinical cure of hepatitis B.This article reviewed and analyzed the indicators related to the prediction of clinical cure of CHB from both host and viral perspectives,with the expectation that they would provide a reference for the practice of clinical cure.

关 键 词：肝炎 乙型 慢性 临床治愈 预测指标 

分 类 号：R51[医药卫生—内科学]